Advertisement

Should You Scoop Up Shares of This Promising Biotech on the Dip?

Should You Scoop Up Shares of This Promising Biotech on the Dip?

The group of technologies that enable gene editing help scientists modify an organism's DNA. Let's look at one of the more prominent pure-play gene-editing stocks on the market: Editas Medicine (NASDAQ: EDIT). This company recently took a nosedive following a disappointing clinical update.